Travere Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Travere Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales grew in 3 of the last 3 years; profit grew in 2 of 3. Steadier than 85% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-2.4×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Higher than 59% of Healthcare companies in United States.
Cash Locked Ratio
$12For every $100 of sales, $12 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $4 tied up three years earlier.
Less money tied up than 74% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 2/3Sales grew in 3 of the last 3 years; profit grew in 2 of 3.
Steadier than 85% of Healthcare companies in United States.
Growth Efficiency Ratio
$66Sales grew 348% in 3 years; of every extra $100 of sales, $66 became extra profit.
Higher than 75% of Healthcare companies in United States.
Asset Productivity Ratio
+348% / -10%In 3 years sales changed by +348% while total assets changed by -10%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
6.4×Debt due within a year is covered 6.4 times by its yearly operating cash.
Higher than 82% of Healthcare companies in United States.
Cash Cushion Ratio
−0%Debt, after subtracting cash, equals 0% of its market value (net debt).
Lower than 68% of Healthcare companies in United States.
Tangible Assets Ratio
81%Of every $100 the company owns, $81 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 51% of Healthcare companies in United States.
Tangible Net Worth Ratio
1%Of every $100 of net worth, $1 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 73% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Travere Therapeutics, Inc. made a loss over the last year. Travere Therapeutics, Inc. owes $0.97 for every $1 it owns. Travere Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossTravere Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
201.54The share price is 201.54 times Travere Therapeutics, Inc.'s book value per share, higher than almost all Healthcare companies in United States.
Market cap
$4.9 BThe total market value of all of Travere Therapeutics, Inc.'s shares at today's price (share price × number of shares), larger than 84% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$25 MWhat Travere Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.26Net worth divided by the number of shares. The share price of $52.43 is 201.5 times this, which is the P/B above.
Return on equity (ROE)
-236.4%Travere Therapeutics, Inc. lost 236.4% of its shareholders' money over the last year, lower than 87% of Healthcare companies in United States.
Owes vs Owns
0.97×Travere Therapeutics, Inc. owes $0.97 for every $1 it owns (high), higher than 86% of Healthcare companies in United States.
Dividend yield
NoneTravere Therapeutics, Inc. does not currently pay a dividend.
Revenue growth
+110%Revenue rose 110% in the year to Dec 2025, and grew 65% a year on average over 3 years.
Profit growth
LossTravere Therapeutics, Inc. made a loss in each of the last two years.
Profit margin
-5.2%Travere Therapeutics, Inc. lost $5 for every $100 of revenue.
Interest cover
Not coveredTravere Therapeutics, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net debtTravere Therapeutics, Inc. had $6 M more debt than cash (net debt) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Travere Therapeutics, Inc.: $4.9 B ÷ $25 M (30 Jun 2026) = 201.5.
What is Travere Therapeutics, Inc.'s return on equity?
Travere Therapeutics, Inc. lost 236.4% of its shareholders' money over the last year, lower than 87% of Healthcare companies in United States.
How much does Travere Therapeutics, Inc. owe compared with what it owns?
Travere Therapeutics, Inc. owes $0.97 for every $1 it owns (high), higher than 86% of Healthcare companies in United States.
Does Travere Therapeutics, Inc. pay a dividend?
No. Travere Therapeutics, Inc. does not currently pay a dividend.
Is Travere Therapeutics, Inc.'s revenue growing?
Revenue rose 110% in the year to Dec 2025, and grew 65% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.